Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder

Munkholm, Klaus; Miskowiak, Kamilla Woznica; Jacoby, Anne Sophie; Vinberg, Maj; Talib, Leda Leme; Gattaz, Wagner F.; Kessing, Lars Vedel

doi:10.1016/j.euroneuro.2018.01.008

Cited by 4 publications

(3 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The detection limit was estimated to be 0.055 ng L −1 based on the response of three times the standard deviation of the zerodose response. It is clear that the prepared sensor achieved improved performance, including lower detection limit and higher sensitivity than those developed in previous reports (Table 1), 20,24,40 which may be of great significance for the early detection of AD.…”

Section: Optimizedmentioning

confidence: 61%

“…This method overcame the drawback related to isotope labeling to attain high sensitivity and reproducibility, but this method requires expensive instrumentation. In addition, while other methods such as quantitative real-time polymerase chain reaction and enzyme immunometric assay are available, they have their own distinct disadvantages. − Electrochemiluminescence (ECL) has attracted significant interest in recent years as a promising approach that can detect subtle changes of target, and has been adopted for clinical detection and investigation. − The detection of GSK-3β using ECL has been reported here for the first time. ECL was found to be an excellent detection system to monitor GSK-3β and it overcome the shortcomings of other methods.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Chemistry Route for Investigation of Alzheimer’s Disease: A Label-Free Electrochemiluminescent Biosensor for Glycogen Synthase Kinase-3 Beta

Tan

2019

ACS Chem. Neurosci.

View full text Add to dashboard Cite

Herein, we report a novel label-free electrochemiluminescent (ECL) biosensor for the detection of glycogen synthase kinase-3 beta (GSK-3β). A simple and feasible sensor was prepared by a two-step process. A polymeric coordination layer of phosphorylated poly vinyl with Zr 4+ was used as the sensory hosting matrix because it efficiently formed a complex. The exterior Zr 4+ can further combine with another phosphate through coordination, and GSK-3β catalyzes the phosphorylation of protein molecules. Thus, the biosensor can detect GSK-3β using luminol as an ECL probe. The ECL intensity of the proposed sensor responded proportionally to the concentration of GSK-3β under direct immersion mode with a linear response in a logarithmic scale over the wide range from 0.5 to 91.5 ng L −1 and a detection limit of 0.055 ng L −1 . Excellent selectivity, stability, and reproducibility were achieved using the prepared biosensor, which has a simple preparation, low cost, and disposable suitability. This work aims to provide a novel tool for early diagnosis and pathological mechanism exploration about AD by detecting inchoate change of GSK-3β content in body fluid, thus to precaution the risk of Alzheimer's disease. It is of great importance for clinical chemistry for the investigation of Alzheimer's disease.

show abstract

Section: Optimizedmentioning

confidence: 61%

Section: Introductionmentioning

confidence: 99%

Clinical Chemistry Route for Investigation of Alzheimer’s Disease: A Label-Free Electrochemiluminescent Biosensor for Glycogen Synthase Kinase-3 Beta

Tan

2019

ACS Chem. Neurosci.

View full text Add to dashboard Cite

show abstract

“…Subsequent studies with, transgenic mice overexpressing GSK-3β indicated that the animals recapitulate manic behavior (Prickaerts et al, 2006), while constitutively active GSK-3 in knock-in mice increases the vulnerability to stress-induced depressive behavior (Polter et al, 2010). Studies in human patients suggested that GSK-3 may be a risk gene in BD, since increased protein levels of GSK-3α/β and increased GSK-3β activity could be detected in peripheral blood cells of BD patients (Li et al, 2010;Munkholm et al, 2018). Similarly, elevated GSK-3β mRNA levels were measured in the hippocampus of patients with major depression (Oh et al, 2010), and polymorphisms in the GSK-3β gene were reported in individuals with BD and major depression (Saus et al, 2011;Terao et al, 2020;, and could be correlated with a therapeutic response to lithium (Benedetti et al, 2005).…”

Section: Psychiatric Disorders Bipolar and Mood Disordersmentioning

confidence: 99%

Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward

Ruiz

Eldar-Finkelman²

2022

Front. Mol. Neurosci.

View full text Add to dashboard Cite

The protein kinase, GSK-3, participates in diverse biological processes and is now recognized a promising drug discovery target in treating multiple pathological conditions. Over the last decade, a range of newly developed GSK-3 inhibitors of diverse chemotypes and inhibition modes has been developed. Even more conspicuous is the dramatic increase in the indications that were tested from mood and behavior disorders, autism and cognitive disabilities, to neurodegeneration, brain injury and pain. Indeed, clinical and pre-clinical studies were largely expanded uncovering new mechanisms and novel insights into the contribution of GSK-3 to neurodegeneration and central nerve system (CNS)-related disorders. In this review we summarize new developments in the field and describe the use of GSK-3 inhibitors in the variety of CNS disorders. This remarkable volume of information being generated undoubtedly reflects the great interest, as well as the intense hope, in developing potent and safe GSK-3 inhibitors in clinical practice.

show abstract

Ciliary neurotrophic factor signaling in the rat orbitofrontal cortex ameliorates stress-induced deficits in reversal learning

et al. 2019

View full text Add to dashboard Cite

Glycogen synthase kinase-3β activity and cognitive functioning in patients with bipolar I disorder

Cited by 4 publications

References 27 publications

Clinical Chemistry Route for Investigation of Alzheimer’s Disease: A Label-Free Electrochemiluminescent Biosensor for Glycogen Synthase Kinase-3 Beta

Clinical Chemistry Route for Investigation of Alzheimer’s Disease: A Label-Free Electrochemiluminescent Biosensor for Glycogen Synthase Kinase-3 Beta

Glycogen Synthase Kinase-3 Inhibitors: Preclinical and Clinical Focus on CNS-A Decade Onward

Ciliary neurotrophic factor signaling in the rat orbitofrontal cortex ameliorates stress-induced deficits in reversal learning

Contact Info

Product

Resources

About